Dr. Jacqueline S. Garcia, MD

Claim this profile

Dana-Farber Cancer Institute

Studies Acute Myeloid Leukemia
Studies T-Lymphoblastic Leukemia/Lymphoma
5 reported clinical trials
10 drugs studied

Area of expertise

1Acute Myeloid Leukemia
Jacqueline S. Garcia, MD has run 4 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
IDH positive
2T-Lymphoblastic Leukemia/Lymphoma
Jacqueline S. Garcia, MD has run 4 trials for T-Lymphoblastic Leukemia/Lymphoma. Some of their research focus areas include:
STAG2 positive
SMC1A positive
RAD21 positive

Affiliated Hospitals

Image of trial facility.
Dana Farber Cancer Institute
Image of trial facility.
Brigham And Women's Hospital

Clinical Trials Jacqueline S. Garcia, MD is currently running

Image of trial facility.

Venetoclax with Chemotherapy

for AML and MDS

This clinical trial involves individuals who have been diagnosed with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and are planning to have an allogeneic hematopoietic stem cell transplant ("bone marrow transplant"). The goal of this research study is to (1) test the safety of adding the study drug, Venetoclax, to a standard of care conditioning regimen for bone marrow transplantation as a possible means of eliminating residual (left-over) disease prior to transplant, (2) to test the safety of combination Venetoclax and azacitidine as "maintenance therapy" after transplant to possibly prevent disease recurrence and (3) to test the safety of combination Venetoclax and oral decitabine/cedazuridine as "maintenance therapy" after transplant to possibly prevent disease recurrence. * The name of the study drug involved in this study is Venetoclax. * It is expected that about 102 people will take part in this research study.
Recruiting1 award Phase 1
Image of trial facility.

Ivosidenib + Venetoclax +/- Azacitidine

for Leukemia

This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ivosidenib and venetoclax with azacitidine may work better in treating patients with hematologic malignancies compared to ivosidenib and venetoclax alone.
Recruiting3 awards Phase 1 & 2

More about Jacqueline S. Garcia, MD

Clinical Trial Related6 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Jacqueline S. Garcia, MD has experience with
  • Venetoclax
  • Azacitidine
  • Decitabine
  • Busulfan
  • Decitabine/cedazuridine
  • Fludarabine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jacqueline S. Garcia, MD specialize in?
Jacqueline S. Garcia, MD focuses on Acute Myeloid Leukemia and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Acute Myeloid Leukemia has involved IDH positive patients, or patients who are undergoing treatment.
Is Jacqueline S. Garcia, MD currently recruiting for clinical trials?
Yes, Jacqueline S. Garcia, MD is currently recruiting for 3 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Jacqueline S. Garcia, MD has studied deeply?
Yes, Jacqueline S. Garcia, MD has studied treatments such as Venetoclax, Azacitidine, Decitabine.
What is the best way to schedule an appointment with Jacqueline S. Garcia, MD?
Apply for one of the trials that Jacqueline S. Garcia, MD is conducting.
What is the office address of Jacqueline S. Garcia, MD?
The office of Jacqueline S. Garcia, MD is located at: Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana-Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.